NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Gastric cancer
Date of first enrollment	07/09/2005
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : TS-1 (tegafur + gimeracil + oteracil potassium) INN of investigational material : TS-1:tegafur, gimeracil, oteracil potassium Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : 80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks

Outcome(s)

Primary Outcome	Efficacy and safety
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	Patients with Stage II (except T1), IIIA or IIIB gastric cancer who received a surgery of curative resection (curability A or B).
Exclude criteria